Diane E. Gingrich

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Bruce Ruggeri, J. B. Singh, Diane E. Gingrich et al. · PubMed · 2003 · 124 citations

Chemoprevention Strategy, Antitumor Efficacy, Tumor Biology +19

Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)

Gregory R. Ott, Mangeng Cheng, Keith S. Learn et al. · Journal of Medicinal Chemistry · 2016 · 88 citations · Full text

Tumor Biology, Clinical Candidate Cep-37440, Lymphoid Neoplasia +14

Depletion of Autoreactive Plasma Cells and Treatment of Lupus Nephritis in Mice Using CEP-33779, a Novel, Orally Active, Selective Inhibitor of JAK2

Lily Lu, Kristine L. Stump, Nate H. Wallace et al. · The Journal of Immunology · 2011 · 75 citations · Full text

Immunology, Immune Regulation, Biological Therapy +25

A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis

Kristine L. Stump, Lily Lu, Paweł Dobrzański et al. · Arthritis Research & Therapy · 2011 · 75 citations · Full text

A New Class of Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors:  Structure−Activity Relationships for a Series of 9-Alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazole-5-ones and the Identification of CEP-5214 and Its Dimethylglycine Ester Prodrug Clinical Candidate CEP-7055

Diane E. Gingrich, D. Rajagopala Reddy, Mohamed Iqbal et al. · Journal of Medicinal Chemistry · 2003 · 74 citations · Full text

Pharmacotherapy, Medicinal Chemistry, Angiogenesis +16